Royalty Pharma plc (RPRX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $67.27 (+2.06%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 10, 2026 | Terence Flynn | Morgan Stanley | $63.00 | -6.3% |
| Feb 12, 2026 | Terence Flynn | Morgan Stanley | $61.00 | -9.3% |
| Jan 30, 2026 | Ashwani Verma | UBS | $49.00 | -27.2% |
| Jul 10, 2025 | Terence Flynn | Morgan Stanley | $54.00 | -19.7% |
| Sep 4, 2024 | Chris Shibutani | Goldman Sachs | $51.00 | -24.2% |
| Jul 11, 2024 | Terence Flynn | Morgan Stanley | $51.00 | -24.2% |
| Jun 7, 2024 | Chris Shibutani | Goldman Sachs | $50.00 | -25.7% |
| Jun 3, 2024 | Ashwani Verma | UBS | $28.00 | -58.4% |
| Jun 13, 2022 | Ashwani Verma | UBS | $47.00 | -30.1% |
Top Analysts Covering RPRX
RPRX vs Sector & Market
| Metric | RPRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.41 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | -1.1% | +153002.0% | +21.5% |
| P/E Ratio | 38.00 | 3.43 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $912M | $916M | $920M | 1 |
| 2027-03-31 | $971M | $975M | $979M | 1 |
| 2027-06-30 | $862M | $866M | $870M | 1 |
| 2027-09-30 | $954M | $958M | $962M | 1 |
| 2027-12-31 | $986M | $990M | $994M | 1 |
| 2028-12-31 | $3.98B | $3.98B | $3.99B | 4 |
| 2029-12-31 | $4.51B | $4.59B | $4.64B | 3 |
| 2030-12-31 | $4.91B | $4.99B | $5.06B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.51 | $1.52 | $1.53 | 1 |
| 2027-03-31 | $1.31 | $1.32 | $1.33 | 1 |
| 2027-06-30 | $1.48 | $1.49 | $1.50 | 1 |
| 2027-09-30 | $1.30 | $1.31 | $1.32 | 1 |
| 2027-12-31 | $1.72 | $1.73 | $1.74 | 1 |
| 2028-12-31 | $6.08 | $6.21 | $6.31 | 1 |
| 2029-12-31 | $6.89 | $7.04 | $7.16 | 1 |
| 2030-12-31 | $7.55 | $7.71 | $7.84 | 1 |
Frequently Asked Questions
What is the analyst consensus for RPRX?
The consensus among 6 analysts covering Royalty Pharma plc (RPRX) is Buy with an average price target of $62.67.
What is the highest price target for RPRX?
The highest price target for RPRX is $63.00, set by Terence Flynn at Morgan Stanley on 2026-04-10.
What is the lowest price target for RPRX?
The lowest price target for RPRX is $28.00, set by Ashwani Verma at UBS on 2024-06-03.
How many analysts cover RPRX?
6 analysts have issued ratings for Royalty Pharma plc in the past 12 months.
Is RPRX a buy or sell right now?
Based on 6 analyst ratings, RPRX has a consensus rating of Buy (2.00/5) with a -1.1% upside to the consensus target of $62.67.
What are the earnings estimates for RPRX?
Analysts estimate RPRX will report EPS of $1.52 for the period ending 2026-12-31, with revenue estimated at $916M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.